脐血输注对急性白血病患者骨髓CFU—GM体外培养及血浆CSA,BPA的影响

以自身对比方法观察急性白血病化疗后骨髓衰竭患者输注脐血和外周血后，骨髓粒、单细胞系集落形成单位（ＣＦＵ－ＧＭ）、血浆集落刺激活性（ＣＳＡ）、爆式集落刺激活性（ＢＰＡ）有外周血白细胞计数（ＷＢＣ）的变化。结果脐血输注后可使患者ＣＦＵ－ＧＭ体外增减显著提高，ＣＳＡ、ＢＰＡ水平显著下降并趋于正常，可在输血量减少情况下，使ＷＢＣ显著增高。     

APL经ATRA诱导后高白细胞征机制的进一步研究

目的：提示ＡＰＬ患者ＡＴＲＡ治疗后高白细胞征的机制。方法：外周血ＷＢＣ计为九及分类按常规进行，体内外粒－单系集落（ＣＦＵ－ＧＭ）按半固体琼脂法进行。ＡＴＲＡ体内实验中的骨髓与脾脏均用２００目风研磨制成单个细胞悬液后计ＷＢＣ数。结果：ＡＴＲＡ临床治疗ＡＰＬ患者可引起明显的ＷＢＣ、早幼粒及较成熟粒系升高。ＣＦＵ－ＧＭ呈现升 高趋势。而ＡＰＬ患者骨髓ＣＦＵ－Ｌ逐渐降低。正常小鼠的体内实验中，ＡＴＲＡ明显     

短程大剂量格拉诺赛特动员APBSC移植(附1例报告)

目的：报导短程大剂量格拉诺赛特（ｒｈＧ－ＣＳＦ）动员外周血造血干细胞,进行自体外周血造血干细胞移植（ＡＰＢＳＣＴ）治疗急性白血病。方法：ｒｈＧ－ＣＳＦ,５００μｇ／ｄ皮下注射４天,第５、６天单采外周血单个核细胞（ＭＮＣ）,行ＣＦＵ－ＧＭ培养,ＣＤ３４＾＋细胞由流式细胞仪检测。于ＭＡＣ方案处理,回输自体外周围血造血干细胞（ＡＰＢＳＣ）。结果：动员后ＣＦＵ－ＧＭ明显增高,ＣＤ３４＾＋细胞增多,骨髓造血     

供者单采外周血中幼稚粒细胞检测的研究

目的：探讨异基因外周血干细胞移植（Ａｌｂ－ＰＢＳＣＴ）供血经细胞集落刺激因子动员后,采集的外周血干细胞（ＰＢＳＣ）移植物中的幼稚粒细胞与单个核细胞（ＭＮＣ）及ＣＤ＾＋３４细胞数之间相关性和移植的剂量标准。方法：对６例Ａｌｌｏ－ＰＢＳＣＴ供者用Ｇ－ＣＳＦ或Ｇ－ＣＳＦ＋ＧＭ－ＣＳＦ进行动员,于动员前及动员后,对外周血及收集的ＮＭＣ收集物中幼稚粒细胞及ＣＤ＾＋３４细胞进行检测计数,并计算出输出患者每公斤     

CM—CSF及IL—4增强树突状细胞免疫功能

目的 探讨粒／巨噬细胞集落刺激因子（ＧＭ－ＣＳＦ）及白介素－４（ＩＬ－４）对正常成人及大肠癌患者树突状细胞（ＤＣ）表现人白细胞抗原（ＨＬＡ）－ＤＲ及Ｂ７等免疫分子表达及其免疫功能的影响。方法 分离正常成人（ｎ＝１０）及大肠癌患者（ｎ＝１０）外周血ＤＣ,以ＧＭ－ＣＳＦ及ＩＬ－４联合刺激正常成人及大肠癌者ＤＣ,检测ＧＭ－ＣＳＦ及ＩＬ－４联合刺激前后ＤＣ表现ＨＬＡ－ＤＲ及Ｂ７表达水平及ＤＣ免疫功能变化。     

骨髓增生异常综合征患者体外CFU-GM、CFU-L培养和细胞遗传学研究

研究了４２例骨髓增生异常综合征患者体外ＣＦＵ－ＧＭ、ＣＦＵ－Ｌ培养和细胞遗传学改变。结果显示，患者ＣＦＵ－ＧＭ明显低于正常对照组（Ｐ＜０．０１），但高于再生障碍性贫血（ＡＡ）（Ｐ＜０．０１），ＣＦＵ－Ｌ高于正常对照组和ＡＡ组（Ｐ＜０．０１）。患者５２．４％存在染色体异常，常见为：＋８、－２２、－Ｘ、－Ｙ、－２０、－７／７ｑ－。ＣＦＵ－ＧＭ减低、ＣＦＵ－Ｌ增高和染色体异常者疗效较正常者差。表明ＣＦＵ－ＧＭ、ＣＦＵ－Ｌ体外培养和细胞遗传学检查可作为ＭＤＳ协助诊断和预测疗效的指标之一。     

肿瘤坏死因子,干扰素和免疫活性肽对癌瘤患者骨髓粒—巨造血祖细…

应用ＣＦＵ－ＧＭ软琼脂培养技术，在体外观察了不同浓度的ｒｈ－ＴＮＦ，ｒｈ－ＩＦＮα－２和ＩＡＰ对９例恶性淋巴瘤和１例睾丸癌患者的骨髓粒、巨造血祖细胞生长的影响。结果表明，在培养体系中，加入ｒｈ－ＴＮＦ５０和１００ｕ／ｍｌ，其ＣＦＵ－ＧＭ较空白对照均明显增多（Ｐ〈０．０５）。ｒｈ－ＩＦＮα－２１０００ｕ／ｍｌ可使ＣＦＵ－ＧＭ减少（Ｐ〈０．０５）。ＩＡＰ似乎对ＣＦＵ－ＧＭ无影响（Ｐ〉０．０５）。集落形     

肿瘤坏死因子、干扰素和免疫活性肽对癌瘤患者骨髓粒－巨造血祖细胞的影响

应用ＣＦＵ－ＧＭ软琼脂培养技术，在体外观察了不同浓度的ｒｈ－ＴＮＦ，ｒｈ－ＩＦＮα－２和ＩＡＰ对９例恶性淋巴瘤和１例睾丸癌患者的骨髓粒－巨造血祖细胞生长的影响。结果表明，在培养体系中，加入ｒｈ－ＴＮＦ５０和１００ｕ／ｍｌ，其ＣＦＵ－ＧＭ较空白对照均明显增多（Ｐ＜０．０５）。ｒｈ－ＩＦＮα－２１０００ｕ／ｍｌ可使ＣＦＵ－ＧＭ减少（Ｐ＜０．０５）。ＩＡＰ似乎对ＣＦＵ－ＧＭ无影响（Ｐ＞０．０５）。集落形态学显示，ｒｈ－ＴＮＦ和ＩＡＰ均能增加巨噬细胞为主形成的集落（Ｐ＜０．０１）。我们认为，该实验为骨髓移植及肿瘤患者在选择应用这些细胞因子上提供了一定的佐证。     

重组人干细胞因子对人类急性髓系白血病干／祖细胞自我更新作用的实验研究

应用无血清液体一半固体二次培养法，观察了重组人干细胞因子（ｒｅｃｏｍｂｉｎａｎｔｈｕｍａｎｓｔｅｍｃｅｌｌｆａｃｔｏｒ，ｒｈＳＣＦ）对人类急性髓系白血病干／祖细胞（ＡＭＬ－ＣＦＵ）自我更新的影响。认为ｒｈＳＣＦ是一作用阶段早于白介素３（ＩＬ－３）和粒／巨噬细胞集落刺激因子（ＧＭ－ＣＳＦ）的造血生长因子（ＨＧＦ）。无论单一，还是与其它ＨＧＦ联合，ｒｈＳＣＦ对绝大部分ＡＭＬ患者，均有强大的维持其ＡＭＬ－ＣＦＵ自我更新的作用。但不同ＦＡＢ亚型及ＦＡＢ亚型相同的患者之间，这种维持作用差异较为显著。提示ＳＣＦ在ＡＭＬ病理过程中起重要作用。     

骨髓增生异常综合征患者体外CFU—GM,CFU—L培养和细胞遗传学研究

研究了４２例骨髓增生异常综合征患者体外ＣＦＵ－ＧＭ、ＣＦＵ－Ｌ培养和细胞遗传学改变。结果显示，患者ＣＦＵ－ＧＭ明显低于正常对照组（Ｐ〈０．０１），但高于再生障碍性贫血（ＡＡ）（Ｐ〈０．０１），ＣＦＵ－Ｌ高于正常对照组和ＡＡ组（Ｐ〈０．０１）。患者５２．４％存在染色体异常，常见为：＋８、－２２、－Ｘ、－Ｙ、－２０、－７／７ｑ＾－。ＣＦＵ－ＧＭ减低、ＣＦＵ－Ｌ增高和染色体异常者疗效较正常者差。表明ＣＦ     

Colony-stimulating and colony-forming cells in peripheral blood as prognostic markers in acute myelogenous leukemia.

Colony-forming cells (CFC) and colony-stimulating activity (CSA) in peripheral blood cells have been studied before and repeatedly during treatment of 32 patients with acute myelogenous leukemia. WBC obtained after Isopaque-dextran separation were cultured in vitro by a double-layer agar technique. Before treatment 19 patients out of 32 had CSA and all had CFC; both CSA and CFC were found in 19 patients. In follow-up studies during treatment, CSA was mainly unaffected during the leukopenic phase, while CFC were suppressed. No CFC were found at WBC counts below 1,000/mm3. This seems to imply that CFC are more sensitive to chemotherapy than colony-stimulating cells. 14 patients entered remission; all of them had CSA. 16 out of the 18 nonresponders lacked on or both types of cells. The presence of CSA and CFC in peripheral blood therefore appears to be a sign of favorable prognosis, while the absence of CSA and/or CFC implies lack of response to treatment. The conclusion from this study is that the presence of both CFC and CSA in peripheral WBC is a sign of a good prognosis. Absence of CFC and/or CSA in the initial sample indicates that the patient is unlikely to respond to conventional therapy with cytotoxic drugs. The presence or absence of CSA alone has a higher prognostic significance than the presence or absence of CFC.     

Effect of chemotherapy on colony-forming unit-granulocyte macrophage from bone marrow and peripheral blood in patients with lung cancer.

The effects of chemotherapy on the growth of colony forming unit-granulocyte macrophage (CFU-GM) from the bone marrow (BM) and peripheral blood (PB) of 8 patients with lung cancer were studied by using recombinant interleukin-3, granulocyte macrophage-colony stimulating factor, and granulocyte-colony stimulating factor. After chemotherapy, the kinetics of CFU-GM depend on the type of chemotherapeutic regimens used: a rebound overshoot of CFU-GM in the PB was seen in the 4 patients treated with cisplatin plus etoposide (PVP) but not in the 4 patients treated with cisplatin plus mitomycin plus vindesine (CMV). In the BM, the recovery of CFU-GM was more retarded in patients treated with CMV relative to that seen in patients treated with PVP. The results obtained in simultaneous cultures revealed the differences between CMV and PVP in the kinetics of chemotherapy-induced myelosuppression. Determination of the optimal timing of in vivo use of hematopoietic growth factors after cytoreductive chemotherapy requires careful experimental design.     

Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy?

BACKGROUND: Data on the incidence of bone marrow (BM) involvement in early-stage diffuse large B-cell lymphoma (DLBCL) are lacking. Although BM biopsy is a safe procedure, it is often poorly tolerated. This analysis aims to assess the incidence of BM involvement and to identify parameters predicting BM involvement in early-stage DLBCL. PATIENTS AND METHODS: One hundred and ninety-two patients with radiological stages 1 and 2 disease were analysed. The data collected were age, sex, presence of B symptoms, white blood cell (WBC) count, platelet count, haemoglobin (Hb), serum lactate dehydrogenase level, serum beta(2)-microglobulin level, presence of extranodal disease, and the presence of bulky disease (defined as >7 cm). RESULTS: Overall incidence of BM involvement was 3.6%. Hb < 10 g/dl (P=0.02), WBC count < 4 x 10(9)/l (P=0.007) and bulky disease (P=0.06) were found to be predictive of BM involvement. Among the 120 patients without any of these three factors, only one patient had BM involvement (0.83%; 95% confidence interval 0.02% to 4.6%). The absence of all three factors gave a negative predictive value of 99.2%. Overall 3-year survival for patients without all three risk factors was 80%. CONCLUSIONS: BM biopsy may be safely omitted in selected patients with early-stage DLBCL.     

肿瘤标记物联合检测对胰腺癌诊断及判断预后的价值

目的：探讨肿瘤标记物联合检测在胰腺癌诊断及判断预后中的价值。方法：分别用ELISA法检测糖抗原－199（CA－199）、胰腺癌胚抗原（PEA）,用比色法检测恶性肿瘤特异性生长因子（TSGF）。结果：48例胰腺癌患才CA－199、PEA、TSGF含量均明显升高,阳性率分别为：85．4％、87．5％和83．3％,三者联合检测诊断胰腺癌的阳性率为100％。胰腺癌患者根治手术后三指标明显降低,与术前比较差异显著（P＜0．01）。结论：CA－199、PEA、TSGF动态检测是诊断胰腺癌、观察胰腺癌疗效、判断预后的重要指标,三者联合可明显提高胰腺癌诊断的阳性率。     

肿瘤病人化疗、免疗及免疫化疗前后NK－IL－2－IFN－r系统变化

本文观察了４６例中晚期肿瘤病人化疗、免疗（抗瘤ｉＲＮＡ及Ｓ－ＴＦ）及免疫化疗前后ＮＫ－ＩＬ－２－ＩＦＮ－ｒ系统及ＷＢＣ等变化。结果发现：（１）肿瘤病人ＮＫ、ＩＬ－２及ＩＦＮ－ｒ活性均显著低于正常人；（２）化疗后除ＷＢＣ明显降低外，其它指标化疗前后均无明显变化；（３）免疫及免疫化疗后各免疫指标均较治疗前显著增加；（４）免化组各免疫指标及ＷＢＣ明显高于化疗组，其中ＩＬ－２及ＩＦＮ－ｒ活性还明显高于免疫组，但免疫组仅ＩＬ－２活性及ＷＢＣ明显高于化疗组。本研究结果表明，抗瘤ｉＲＮＡ及Ｓ－ＴＦ不仅可恢复肿瘤宿主的免疫力，而且与化疗联用，还可能降低化疗的毒副反应，协调肿瘤病人ＮＫ－ＩＬ－２－ＩＦＮ－ｒ系统的抗癌功能。     

应用多种血管内皮模型研究大肠癌细胞及其球体的侵袭特性

应用人羊膜基膜──内皮细胞模型、人胎儿主动脉内膜器官培养等多种血管内皮模型，通过浸润力、粘附性定量检测与形态学观察相结合的方法，比较研究了两种人大肠癌细胞及其多细胞球体（ｍｕｌｔｉｃｅｌｌｕｌａｒＳｐｈｅｒｏｉｄ）对血管内皮（ＨＥＣ）、基膜（ＨＡＢＭ）及其间质（Ｓｔｒｏｍａ、ＳＴ）的体外侵袭作用。结果表明，ＨＲ－８３４８细胞及其球体对血管内皮具有较强的粘附作用（粘附率分别为２５．９±３．６％、３３．１±４．２％）．但对不同基质的粘附率有显著性差异（ＨＡＢＭ＞ＨＥＣ＞ＳＴ，Ｐ＜０．０１）。在相同实验条件下，球体比相同细胞数量的单细胞具有更高的浸润力（Ｐ＜０．０１），提示癌细胞球体具有高侵袭特性。     

脐血与成人血成分、T淋巴细胞亚群及正常人骨髓集落形成的比较研究

目的：研究脐血,成人外周血及骨髓的特性,方法：采用全自动血细胞分析仪及流式细胞仪分别测定济血,成人外周血的血成分及T巴细胞亚群,采用集落形成试验观察脐血,外周因及骨髓的CTU－GM和BFU－E的产率变化,结果：脐血的各种血成分均显著高于外周血,CD,CD3明显低于外周血,而CD4,CD8的表达与外周血相似,经细胞因子诱导后,脐血中的CUF0－GM及BFU－E显著升高,结论：脐血富含造血干细胞,是重建造血与免疫系统的血细胞新来源。     

Lack of differential sensitivity of normal hematopoietic stem cells and murine lymphoblastic leukemic cells to a lysosomotropic agent, N-dodecyl morpholine

The effect of N-dodecyl morpholine (NDM), a lysosomotropic compound, on the clonogenic capacity of GK15, Sp2.0, Hb131, and L1210 lymphoblastic tumor cells and CFU-GM and CFU-S progenitor cells from DBA/2 mice was measured in order to evaluate the potential use of this compound for the purging of tumor-contaminated bone marrow (BM) in autologous BM transplantation. The growth of clonogenic tumor cells from all of the tested cell lines was inhibited with doses of NDM that also killed 100% CFU-GM and CFU-S, and no optimal dose could be found in this animal model to purge marrow while sparing sufficient stem cells to ensure engraftment in syngeneic BM transplantation.     

Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy

Background and purposeTo identify clinical and dosimetric factors associated with hematologic toxicity (HT) during chemoradiotherapy for rectal cancer.Materials and methodsWe analyzed 120 rectal cancer patients treated with neoadjuvant pelvic radiotherapy (PRT) with concurrent 5-fluorouracil-based chemotherapy. The coxal (ilium, ischium, and pubis) bone marrow (BM), sacral BM, and femoral BM were contoured and dose-volume parameters were extracted. Associations between cell count trend and clinical predictors were tested using repeated-measures analysis of variance (ANOVA) test. Associations between clinical variables, Vx (percentage volume receiving x Gy), and cell count ratio at nadir were tested using linear regression models.ResultsNadirs for white blood cell count (WBC), absolute neutrophil count (ANC), and platelets (PLT) occurred in the second week of PRT and the fifth week for hemoglobin and absolute lymphocyte count (ALC). Using cell count ratio, patients treated with 3DCRT had a lower WBC ratio trend during PRT compared to patients treated with IMRT (p = 0.04), and patients ⩾59 years of age had a lower hemoglobin ratio trend during PRT (p = 0.02). Using absolute cell count, patients treated with 3DCRT had lower ANC cell count trend (p = 0.03), and women had lower hemoglobin cell count trend compared to men (p = 0.03). On univariate analysis, use of 3DCRT was associated with a lower WBC ratio at nadir (p = 0.02). On multiple regression analysis using dosimetric variables, coxal BM V45 (p = 0.03) and sacral BM V45 (p = 0.03) were associated with a lower WBC and ANC ratio at nadir, respectively.ConclusionsHT trends during PRT revealed distinct patterns: WBC, ANC, and PLT cell counts reach nadirs early and recover, while hemoglobin and ALC decline steadily. Patients who were treated with 3DCRT and older patients experienced lower cell count ratio trend during PRT. Dosimetric constraints using coxal BM V45 and sacral BM V45 can be considered.     

Monitoring of residual hematopoiesis after total body irradiation in humans as a model for accidental x-ray exposure: dose-effect and failure of ex vivo expansion of residual stem cells in view of autografting

PURPOSE: To evaluate the residual hematopoiesis at different levels of total body irradiation (TBI) dose in bone marrow (BM) and peripheral blood (PB), and to study the dose-effect relationship on hematopoietic immature and mature progenitors. We also investigated the possibility of expanding ex vivo the residual progenitors exposed to different dose levels of TBI. METHODS AND MATERIALS: Eight patients treated for AML (n = 3) and myeloma (n = 5) were included. BM and PB samples were harvested before TBI and after doses of: 5 Gy. Mononuclear cells (MNCs) were assayed for burst-forming unit erythroid (BFU-E), granulocyte-forming unit macrophage (CFU-GM), and long-term culture initiating cells (LTC-ICs). Ex vivo expansion: MNCs (after irradiation and controls) were suspended in long-term cultures and expanded with a combination of five cytokines. RESULTS: CD34+ cells were detectable at 10 Gy. We observed a significant decrease of CFU-GM and BFU-E, respectively, to 13.5% and 8.5% of baseline values for doses 相似文献